---
figid: PMC3925679__nihms547680f2
figtitle: Bile Acid Receptors in Non-alcoholic Fatty Liver Disease
organisms:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
pmcid: PMC3925679
filename: nihms547680f2.jpg
figlink: /pmc/articles/PMC3925679/figure/F2/
number: F2
caption: Bile acids (CA and CDCA), synthetic FXR agonists (GW4064, INT-747 and WAY-362450)
  and a dual FXR/TGR5 agonist (INT-767) activate hepatic FXR, resulting in modulation
  of hepatic and plasma lipid homeostasis. FXR lowers hepatic triglyceride levels
  likely through multiple mechanisms. The FXR-SHP-SREBP-1c pathway does not appear
  to play a role in this process [, –]. Instead, other genes/pathways, including FGF21
  [], ChREBP [], PPARα [, ], and AKR1B7 [] may play a role in FXR-mediated reduction
  in hepatic triglyceride levels. Activation of FXR regulates plasma cholesterol and
  triglyceride levels through modulating several genes, including SR-BI [], LDLR [],
  Syndecan-1[], VLDLR [], ApoCII, ApoCIII [] and ANGPTL3 [].
papertitle: Bile Acid Receptors in Non-alcoholic Fatty Liver Disease.
reftext: Yuanyuan Li, et al. Biochem Pharmacol. ;86(11):1517-1524.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9476981
figid_alias: PMC3925679__F2
figtype: Figure
organisms_ner:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
redirect_from: /figures/PMC3925679__F2
ndex: f4f9c088-defa-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3925679__nihms547680f2.html
  '@type': Dataset
  description: Bile acids (CA and CDCA), synthetic FXR agonists (GW4064, INT-747 and
    WAY-362450) and a dual FXR/TGR5 agonist (INT-767) activate hepatic FXR, resulting
    in modulation of hepatic and plasma lipid homeostasis. FXR lowers hepatic triglyceride
    levels likely through multiple mechanisms. The FXR-SHP-SREBP-1c pathway does not
    appear to play a role in this process [, –]. Instead, other genes/pathways, including
    FGF21 [], ChREBP [], PPARα [, ], and AKR1B7 [] may play a role in FXR-mediated
    reduction in hepatic triglyceride levels. Activation of FXR regulates plasma cholesterol
    and triglyceride levels through modulating several genes, including SR-BI [],
    LDLR [], Syndecan-1[], VLDLR [], ApoCII, ApoCIII [] and ANGPTL3 [].
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Scarb1
  - Nr1h4
  - Akr1b7
  - Pcsk9
  - Ldlr
  - Ppara
  - Nr0b2
  - Pdk4
  - Mlxipl
  - Vldlr
  - Tg
  - Cd320
  - Cd36
  - Cpe
  - Apoc2
  - Fgf21
  - Fgf15
  - Angptl3
  - Lpl
  - Srebf1
  - Fat1
  - RGD1565355
  - Fgf19
  - SCARB1
  - HSD11B1
  - ALB
  - APOA1
  - APOA2
  - APOE
  - CLU
  - NR1H4
  - PCSK9
  - LDLR
  - PPARA
  - NR0B2
  - PDK4
  - MLXIPL
  - VLDLR
  - TG
  - CD36
  - FAT1
  - APOC2
  - FGF21
  - FGF19
  - ANGPTL3
  - LPL
  - LCP1
  - GW4064
  - WAY-362450
---
